Banzel
(Rufinamide)Phase 3Small molecule
EisaiBanzel is one of 54 small molecule programs targeting Lennox-Gastaut syndrome. It is currently in Phase 3.
2
Indications
12
Total Trials
0
Active Trials
53
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
109 competitors in Seizure
#DrugCompanyPhaseTrials
1Briviact
UCBPhase 3
Afinitor
NovartisPhase 3
Fintepla
IImmedica Pharma AB
Phase 3
E2007
EisaiPhase 3
Epsom Salt
FFresenius Kabi Oncology Ltd.
Phase 3
Ativan
BBausch Health Americas, Inc.
Phase 3
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
SPM 929
UCBPhase 3
Valproate Sodium
SanofiPhase 3
Carisbamate
SSK Life Science, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lennox-Gastaut syndrome4 trials
Show 1 more trial
Seizure3 trials
Tics2 trials
Pharmacokinetics and Tolerability of Rufinamide in Healthy Chinese Subjects
Completed·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT02332174·40 enrolled
1 more indication
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Nov 14, 2008
BANZEL
NDA NDA021911
Mar 3, 2011
BANZEL
NDA NDA201367
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rufinamide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]